Reuters

SHANGHAI (Reuters) - China's securities watchdog does not expect a near-term spike in delistings, it said on Thursday, after investors dumped shares in small-cap companies on fears they could be kicked off the market as Beijing weeds out weaker firms. The "survival of the fittest" mechanism is gradually taking shape but in the short term, there will not be an "evident increase" in the number of delisted companies, the China Securities Regulatory Commission... (continue reading...)

WASHINGTON (Reuters) - The chair of the National Transportation Safety Board said Thursday the February 2023 near-collision between a FedEx plane and a Southwest Airlines jet in Austin, Texas could have been catastrophic without the actions of the cargo carrier pilots.

The NTSB is meeting to determine the probable cause and make safety recommendations in the wake of a series of dangerous near-collision incidents last year that raised concerns about... (continue reading...)

By Emma Farge

GENEVA (Reuters) - The head of the International Labour Organization on Thursday criticized the decimation of Palestinian workers' labour rights since the start of the Israel-Hamas war in Gaza and called for an end to new restrictions blocking them from working in Israel.

Israel's treatment of Palestinian workers, under scrutiny for decades by the U.N. labour body, has increased since the Oct. 7 war with criticism focused on... (continue reading...)

By Leah Douglas and Tom Polansek

(Reuters) - Dairy cows infected with avian flu in five U.S. states have died or been slaughtered by farmers because they did not recover, state officials and academics told Reuters.

Reports of the deaths suggest the bird flu outbreak in cows could take a greater economic toll in the farm belt than initially thought. Farmers have long culled poultry infected by the virus, but cows cost much more to raise... (continue reading...)

(Reuters) -A panel of outside experts to the U.S. health regulator will meet on Monday to vote on safety and efficacy data for Lilly's (NYSE: LLY) donanemab, a potential rival to Eisai and Biogen's Leqembi, and make recommendations to the FDA.

Both the drugs are antibodies designed to remove toxic beta amyloid plaques from the brains of people with early Alzheimer's disease.

The panel will also vote on whether benefits of the treatment... (continue reading...)